世界の黄斑浮腫治療市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)

GlobalInfoResearchが発行した調査報告書(GIR20SP04562)
◆英語タイトル:Global Macular Edema Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025
◆商品コード:GIR20SP04562
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2020年9月18日(※2024年版があります。お問い合わせください。)
◆ページ数:122
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、黄斑浮腫治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。黄斑浮腫治療の種類別市場規模(レーザー治療、抗VEGF注射、抗炎症治療、硝子体切除術)、用途別市場規模(嚢胞性黄斑浮腫(CME)、糖尿病性黄斑浮腫(DME))、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Allergan、Bausch & Lomb、Regeneron Pharmaceuticals、Novartis、Boehringer Ingelheim、Roche、ActiveSite Pharmaceuticals、Bayer、Pfizer、Aciont、Astellas Pharma、Adverum Biotechnologies、Araim Pharmaceuticals、Aerpio Therapeutics、Ampio Pharmaceuticals
・地域別グローバル市場分析 2015年-2020年
・黄斑浮腫治療の北米市場(アメリカ、カナダ、メキシコ)
・黄斑浮腫治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・黄斑浮腫治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・黄斑浮腫治療の南米市場(ブラジル、アルゼンチン)
・黄斑浮腫治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:レーザー治療、抗VEGF注射、抗炎症治療、硝子体切除術
・用途別分析:嚢胞性黄斑浮腫(CME)、糖尿病性黄斑浮腫(DME)
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The global Macular Edema Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Macular Edema Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Macular Edema Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Macular Edema Therapeutics market has been segmented into:
Laser Treatment
Anti-VEGF Injection
Anti-Inflammatory Treatment
Vitrectomy

By Application, Macular Edema Therapeutics has been segmented into:
Cystoid Macular Edema (CME)
Diabetic Macular Edema(DME)

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Macular Edema Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Macular Edema Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Macular Edema Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Macular Edema Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Macular Edema Therapeutics Market Share Analysis
Macular Edema Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Macular Edema Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Macular Edema Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Macular Edema Therapeutics are:
Allergan
Bausch & Lomb
Regeneron Pharmaceuticals
Novartis
Boehringer Ingelheim
Roche
ActiveSite Pharmaceuticals
Bayer
Pfizer
Aciont
Astellas Pharma
Adverum Biotechnologies
Araim Pharmaceuticals
Aerpio Therapeutics
Ampio Pharmaceuticals

【レポートの目次】

Table of Contents

1 Macular Edema Therapeutics Market Overview
1.1 Product Overview and Scope of Macular Edema Therapeutics
1.2 Classification of Macular Edema Therapeutics by Type
1.2.1 Global Macular Edema Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Macular Edema Therapeutics Revenue Market Share by Type in 2019
1.2.3 Laser Treatment
1.2.4 Anti-VEGF Injection
1.2.5 Anti-Inflammatory Treatment
1.2.6 Vitrectomy
1.3 Global Macular Edema Therapeutics Market by Application
1.3.1 Overview: Global Macular Edema Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Cystoid Macular Edema (CME)
1.3.3 Diabetic Macular Edema(DME)
1.4 Global Macular Edema Therapeutics Market by Regions
1.4.1 Global Macular Edema Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Macular Edema Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Macular Edema Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Macular Edema Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Macular Edema Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Macular Edema Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Macular Edema Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Allergan
2.1.1 Allergan Details
2.1.2 Allergan Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Allergan SWOT Analysis
2.1.4 Allergan Product and Services
2.1.5 Allergan Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Bausch & Lomb
2.2.1 Bausch & Lomb Details
2.2.2 Bausch & Lomb Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Bausch & Lomb SWOT Analysis
2.2.4 Bausch & Lomb Product and Services
2.2.5 Bausch & Lomb Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Regeneron Pharmaceuticals
2.3.1 Regeneron Pharmaceuticals Details
2.3.2 Regeneron Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Regeneron Pharmaceuticals SWOT Analysis
2.3.4 Regeneron Pharmaceuticals Product and Services
2.3.5 Regeneron Pharmaceuticals Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Boehringer Ingelheim
2.5.1 Boehringer Ingelheim Details
2.5.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Boehringer Ingelheim SWOT Analysis
2.5.4 Boehringer Ingelheim Product and Services
2.5.5 Boehringer Ingelheim Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Roche SWOT Analysis
2.6.4 Roche Product and Services
2.6.5 Roche Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 ActiveSite Pharmaceuticals
2.7.1 ActiveSite Pharmaceuticals Details
2.7.2 ActiveSite Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 ActiveSite Pharmaceuticals SWOT Analysis
2.7.4 ActiveSite Pharmaceuticals Product and Services
2.7.5 ActiveSite Pharmaceuticals Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bayer
2.8.1 Bayer Details
2.8.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bayer SWOT Analysis
2.8.4 Bayer Product and Services
2.8.5 Bayer Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Pfizer SWOT Analysis
2.9.4 Pfizer Product and Services
2.9.5 Pfizer Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Aciont
2.10.1 Aciont Details
2.10.2 Aciont Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Aciont SWOT Analysis
2.10.4 Aciont Product and Services
2.10.5 Aciont Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.11 Astellas Pharma
2.11.1 Astellas Pharma Details
2.11.2 Astellas Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Astellas Pharma SWOT Analysis
2.11.4 Astellas Pharma Product and Services
2.11.5 Astellas Pharma Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.12 Adverum Biotechnologies
2.12.1 Adverum Biotechnologies Details
2.12.2 Adverum Biotechnologies Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Adverum Biotechnologies SWOT Analysis
2.12.4 Adverum Biotechnologies Product and Services
2.12.5 Adverum Biotechnologies Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.13 Araim Pharmaceuticals
2.13.1 Araim Pharmaceuticals Details
2.13.2 Araim Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Araim Pharmaceuticals SWOT Analysis
2.13.4 Araim Pharmaceuticals Product and Services
2.13.5 Araim Pharmaceuticals Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.14 Aerpio Therapeutics
2.14.1 Aerpio Therapeutics Details
2.14.2 Aerpio Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Aerpio Therapeutics SWOT Analysis
2.14.4 Aerpio Therapeutics Product and Services
2.14.5 Aerpio Therapeutics Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.15 Ampio Pharmaceuticals
2.15.1 Ampio Pharmaceuticals Details
2.15.2 Ampio Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Ampio Pharmaceuticals SWOT Analysis
2.15.4 Ampio Pharmaceuticals Product and Services
2.15.5 Ampio Pharmaceuticals Macular Edema Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Macular Edema Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Macular Edema Therapeutics Players Market Share
3.2.2 Top 10 Macular Edema Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Macular Edema Therapeutics Revenue and Market Share by Regions
4.2 North America Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Macular Edema Therapeutics Revenue by Countries
5.1 North America Macular Edema Therapeutics Revenue by Countries (2015-2020)
5.2 USA Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Macular Edema Therapeutics Revenue by Countries
6.1 Europe Macular Edema Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Macular Edema Therapeutics Revenue by Countries
7.1 Asia-Pacific Macular Edema Therapeutics Revenue by Countries (2015-2020)
7.2 China Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Macular Edema Therapeutics Revenue by Countries
8.1 South America Macular Edema Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Macular Edema Therapeutics by Countries
9.1 Middle East & Africa Macular Edema Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Macular Edema Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Macular Edema Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Macular Edema Therapeutics Market Forecast by Type (2019-2024)
10.3 Laser Treatment Revenue Growth Rate (2015-2025)
10.4 Anti-VEGF Injection Revenue Growth Rate (2015-2025)
10.5 Anti-Inflammatory Treatment Revenue Growth Rate (2015-2025)
10.6 Vitrectomy Revenue Growth Rate (2015-2025)
11 Global Macular Edema Therapeutics Market Segment by Application
11.1 Global Macular Edema Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Macular Edema Therapeutics Market Forecast by Application (2019-2024)
11.3 Cystoid Macular Edema (CME) Revenue Growth (2015-2020)
11.4 Diabetic Macular Edema(DME) Revenue Growth (2015-2020)
12 Global Macular Edema Therapeutics Market Size Forecast (2021-2025)
12.1 Global Macular Edema Therapeutics Market Size Forecast (2021-2025)
12.2 Global Macular Edema Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Macular Edema Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Macular Edema Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Macular Edema Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Macular Edema Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Macular Edema Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

...

【掲載企業】

Allergan、Bausch & Lomb、Regeneron Pharmaceuticals、Novartis、Boehringer Ingelheim、Roche、ActiveSite Pharmaceuticals、Bayer、Pfizer、Aciont、Astellas Pharma、Adverum Biotechnologies、Araim Pharmaceuticals、Aerpio Therapeutics、Ampio Pharmaceuticals

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の黄斑浮腫治療市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)(Global Macular Edema Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。